^
Association details:
| Biomarker: | HER-2 amplification |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | Kadcyla (ado-trastuzumab emtansine) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers
Excerpt:
...- For Cohorts 2, 3, 4, 5, 6 documented HER2 amplification identified through next generation sequencing by MSK-IMPACT or at another Clinical Laboratory Improvement Amendments (CLIA) laboratory, or documented HER2 amplification by in-situ hybridization (ISH) with HER2/CEP17 ratio ≥2.0 at a CLIA laboratory....
Trial ID:
Source:
Title:
Final analysis of multi-histology basket trial expansion of ado-trastuzumab emtansine in patients with HER2 amplified cancers.
Published date:
05/25/2023
Excerpt:
Ado-trastuzumab emtansine showed promising efficacy in patients with HER2 amplified lung and salivary gland cancers as identified by NGS, meeting the primary endpoint.
DOI:
10.1200/JCO.2023.41.16_suppl.3025
Trial ID:
Source:
Title:
A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers.
Published date:
05/16/2018
Excerpt:
Ado-trastuzumab emtansine showed efficacy in patients with HER2 amplified lung, endometrial, salivary gland, biliary tract and ovarian cancers as identified by NGS.
DOI:
10.1200/JCO.2018.36.15_suppl.2502
Trial ID:
